Marketwire
Fully automated, digital platform can get results to physicians in as little as 12 hours post-inoculation, compared to traditional 48 hour protocols
MISSISSAUGA, ONTARIO--(Marketwired - Sept. 19, 2013) - CML HealthCare Inc. (TSX:CLC)
| WHO: |
CML HealthCare Inc. |
| |
|
| WHAT: |
Ribbon cutting and tours of North America's first BD Kiestra ™ Total Laboratory Automation (TLA) systems at CML's Central Laboratory. Combined, the two systems can perform 400 to 500 inoculations per hour on all specimen types (liquid and non-liquid), in addition to tracking the automated incubation and digital images of over 6500 inoculated media plates daily. |
| |
|
| |
Tours of the laboratory will be provided to elected officials, business partners and media, who will be able to film/photograph the platform in full operation. |
| |
|
| WHEN: |
Thursday, September 19 at 1:30 p.m. ET at CML's Central Laboratory, |
| |
6560 Kennedy Road, Mississauga, L5T 2X4 |
About the BD Kiestra™ Total Laboratory Automation system at CML HealthCare
As a leading Canadian community-based, medical diagnostic services provider, with a network of 114 Client C.A.R.E. Centres in Ontario, CML processes 8,000 - 10,000 microbiology tests each day. The BD Kiestra™ TLA system automates the manual processes associated with inoculating and incubating microbiology specimens, and uses digital imaging of the inoculated specimens to shorten the time to detect bacterial growth. The impacts of this technology include increased efficiency, enhanced quality, and faster turn-around time. The BD Kiestra™ TLA system, integrated with other rapid identification technologies at CML, represent a paradigm shift in the delivery of microbiology testing. They transform a previously manual discipline into an automated process that generates a more rapid diagnosis that can better guide treatment decisions and appropriate antibiotic utilization.
The BD Kiestra™ installation at CML has the capacity to perform 400 to 500 inoculations per hour on prepared media plates, tubes, and slides. Each inoculated specimen is uniquely identified by bar-code for full tracking and traceability. The increased precision and reproducibility of the system allow for improved recovery of infection-causing bacteria. A magnetic bead is used to achieve uniform spreading of the specimen and create distinct colonies for examination. A track system automatically delivers and retrieves plates from on-line incubators, and utilizes digital imaging technology to track organism growth. By tracking when specimen images are ready to analyze, the system directs technologists to more quickly identify suspicious organisms for rapid identification using technology integrated with the BD Kiestra™platform. The end result is reduction, by more than half, of the turn-around time to identify organisms, compared to traditional protocols.
About CML HealthCare Inc.
Based in Mississauga, Ontario, CML HealthCare Inc. is a leading Canadian community-based, medical diagnostic services provider. In addition to its network of 114 Client C.A.R.E. Centres in Ontario and 82 imaging centres in Ontario and British Columbia, CML operates three subsidiaries: 1) Hemostasis Reference Laboratory, focused on specialized coagulation testing and equipment calibration for international customers; 2) CML Bioanalytics, a specialty laboratory providing customized clinical trial testing for the biotechnology and pharmaceutics industries; and 3) Rocky Mountain Analytical, providing specialized testing for naturopaths and physicians practicing integrated medicine in Canada.
The Company entered into a Plan of Arrangement, which provides for LifeLabs Ontario Inc. ("LifeLabs") to acquire all issued and outstanding common shares of CML. The Arrangement is expected to become effective on October 1, 2013, after customary conditions contained in the Arrangement Agreement between CML and LifeLabs have been satisfied or waived by the parties.
For more information, please visit www.cmlhealthcare.com or follow CML on Twitter @cmlhealthcare.